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Purpose: To report corneal epithelial defects (CEDs) and delayed epithelial healing 
after intravitreal bevacizumab (IVB) injection and to describe delayed corneal epithelial 
healing with topical administration of bevacizumab in an experimental rabbit model.
Methods: A retrospective chart review was performed on 850 eyes of 850 patients 
with neovascular eye disease and diabetic macular edema who had received 1.25 
to 2.5 mg IVB. In the experimental arm of the study, photorefractive keratectomy 
was used to create a 3 mm CED in the right eyes of 18 New Zealand rabbits which 
were then randomized to three equal groups. All rabbits received topical antibiotics, 
additionally those in group A received topical bevacizumab and animals in group B 
were treated with topical corticosteroids. The rate of epithelial healing was assessed 
at different time points using slitlamp photography.
Results: In the clinical study, seven eyes of seven subjects developed CEDs the day 
after IVB injection. All of these eyes had preexisting corneal edema. The healing 
period ranged from 3 to 38 days (average 11 days) despite appropriate medical 
management. In the experimental study, topical bevacizumab and corticosteroids 
both significantly hindered corneal epithelial healing at 12 and 24 hours.
Conclusion: Bevacizumab was demonstrated to cause CEDs in clinical settings. 
Moreover, corneal epithelial healing was delayed by topical application of bevacizumab, 
in the experimental model. These short-term results suggest that corneal edema may 
be considered as a risk factor for epithelial defects after IVB.
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INTRODUCTION
The vascular endothelial growth factor (VEGF) 
has been considered as the major angiogenic 
stimulus for ocular neovascularization.1-6 
Bevacizumab  (Avastin),  a  full-length 
humanized monoclonal antibody, binds to 
and inhibits all biologically active isoforms of 
VEGF-A.1,7 Although FDA-approved only for 
intravenous administration in the treatment 
of metastatic colorectal cancer and other 
malignant tumors, this drug is widely used Epithelial Defects after IVB; Colombres et al
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off-label in various ophthalmic conditions. 
An intraocular injection of 1.25 mg/0.05 ml 
bevacizumab has been reported to markedly 
promote regression of ocular neovascularization 
in experimental and clinical studies.8,9 Several 
reports have demonstrated that this drug can 
be injected safely and effectively into the eye 
for treatment of a variety of ocular disorders 
such as age-related macular degeneration 
(AMD), proliferative diabetic retinopathy 
(PDR) and neovascular glaucoma (NVG), 
among others.10-12 However in 2006, adverse 
drug-related events associated with intravitreal 
bevacizumab (IVB) treatment were reported 
in retrospective studies on a limited number 
of patients.13,14
Several growth factors have been implicated 
in corneal epithelial repair.15 Cytokines, 
growth  factors,  and  matrix-degrading 
enzymes have an important role in ocular 
surface inflammation, wound healing, and 
angiogenesis. Recently, several reports have 
suggested that small doses of bevacizumab, 
delivered topically or subconjunctivally 
for treatment of corneal neovascularization 
and pterygia, do not cause serious adverse 
effects.16-19 On the other hand, it has been 
shown that the human corneal epithelium 
expresses VEGF-A and its receptors.20 These 
observations may suggest a role for VEGF-A 
not only in corneal neovascularization, but also 
in other physiologic or pathologic conditions 
such as corneal wound healing.
The present study was designed to 
determine the effect of IVB on the corneal 
epithelium and to assess, in an experimental 
model, the time required for corneal epithelial 
healing after exposure to topical bevacizumab.
METHODS
Clinical Study
A retrospective chart review was performed 
on 850 eyes of 850 individuals including 548 
male and 302 female subjects with mean age of 
69±19 (range 29 to 73) years who had received 
IVB from January 1, 2006 to January 1, 2009 
for different ocular conditions including AMD 
(546 eyes), diabetic macular edema (DME, 259 
eyes), and NVG secondary to PDR (32 eyes) 
or central retinal vein occlusion (13 eyes). All 
patients who received IVB during this time 
period were included in the review, without 
exceptions. The patients had received 1.25 to 
2.5 mg of intraocular bevacizumab.
The study received Institutional Review 
Board approval from the Oulton-Romagosa 
Joint Committee on Clinical Investigation 
(CIEIS Oulton-Romagosa) and each patient 
signed a written informed consent form prior 
to treatment.
Experimental Study
Eighteen male New Zealand rabbits (average 
weight 345±42 g) were kept under a 12 hour 
light/12 hour dark schedule with free access 
to food and water. All experiments were 
conducted in accordance with the Association 
for Research in Vision and Ophthalmology 
(ARVO) Statements for the Use of Animals in 
Ophthalmic and Vision Research.
The rabbits were anesthetized using 
intramuscular xylazine hydrochloride (5 mg/
kg of body weight) and ketamine hydrochloride 
(35 mg/kg of body weight). After topical 
application of 1% tetracaine chlorhydrate 
Patient  Age / Sex Previous Diagnosis IVB Dose (mg/ml) Healing Time (days) Complications
1 72/F AMD 1.25 7 None
2 56/F Diabetes (NVI) 1.25 10 None
3 62/M CRVO (NVI) 2.5 7 None
4 52/M Diabetes (NVI) 2.5 5 None
5 62/F Diabetes (NVI) 2.5 7 None
6 64/F Diabetes (DME) 2.0 3 None
7 57/F Diabetes (PDR) 2.0 38 Infectious keratitis
IVB, intravitreal bevacizumab; F, female; M, male; AMD, age-related macular degeneration; NVI, iris neovascularization; CRVO, 
central retinal vein occlusion; DME, diabetic macular edema; PDR, proliferative diabetic retinopathy
Table 1. Clinical data of seven subjects who developed epithelial defects after IVBEpithelial Defects after IVB; Colombres et al
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(Anestalcon, Alcon Laboratories, Fort Worth, 
TX, USA) and 5% povidone iodine (Betadine, 
Alcon Laboratories, Fort Worth, TX, USA), 
photorefractive keratectomy (PRK) was 
performed to induce a central corneal lesion, 
3 mm in diameter and 120 μm in depth, in the 
right eye of all 18 animals using the Compak-200 
MiniExcimer laser (LaserSight Technologies 
Inc., Winter Park, FL, USA).
The rabbits were randomly allocated into 
3 groups of 6 animals. All three groups were 
treated with topical 0.3% ofloxacin eye drops 
four times daily. Additionally, groups A and 
B received 2.5 mg/ml topical bevacizumab 
(Avastin, Genetech Inc., San Francisco, CA, 
USA) and 1% prednisolone acetate (Prednefrin 
Forte, Allergan, Irvine, CA, USA) eye drops 
twice a day, respectively. Within each study 
group, the fellow untreated eye received the 
same medical regimen employed for the right 
eye. Bevacizumab eye drops were prepared from 
the commercially available solution diluted in 
0.9% preservative-free artificial tears to reach 
a concentration of 2.5 mg/ml.
Measurement of corneal epithelial defects 
(CEDs) was performed after fluorescein staining 
using slitlamp photography (SL-7E, Topcon, 
Tokyo, Japan) at different time points after 
injury (12, 24, 48 and 72 hours), until the lesions 
were fully healed. Images were evaluated using 
an analysis software (Image Analyzer 1.32). 
All observations were performed by a single 
masked examiner.
Data were analyzed statistically using 
GraphPad Prism version 3.0 (GraphPad Software 
Inc., San Diego, CA, USA). The Newman-Keuls 
multiple comparison test was used to compare 
data within each experiment and the unpaired 
t-test was used to compare data between 
two variables. P-values less than 0.05 were 
considered as statistically significant.
RESULTS
Clinical Study
CEDs developed in 7 patients treated with IVB. 
Six of them were diabetic (85.7%), of whom 
4 subjects had NVG, 4 had PDR and 1 had 
Figure 1. Clinical stages of CED healing times in rabbit 
corneas after exposure to different medications following 
PRK.  Figures  1A,  B,  C,  and  D  show  corneas  treated 
with topical bevacizumab in addition to antibiotic eye 
drops (ofloxacin) immediately after PRK, at 12 hours, 
24 hours, and 48 hours following treatment (group A). 
Figures 1E, F, G, and H correspond to group B, which 
received topical steroids in addition to topical ofloxacin 
following PRK. Figure 1I, J, K, and L (group C) received 
only topical ofloxacin. These figures correspond to CEDs 
immediately after PRK treatment, at 12 hours, 24 hours, 
and 48 hours following PRK.Epithelial Defects after IVB; Colombres et al
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DME. The single remaining patient had been 
treated for AMD (Table 1). All patients had 
preexisting corneal edema, including the AMD 
patient who had concomitant Fuchs’ corneal 
endothelial dystrophy.
The dose of IVB ranged from 1.25 mg to 
2.5 mg (Table 1). All 7 eyes developed CED 
the day after uneventful IVB injection. None of 
the patients without corneal edema developed 
such a complication and it is worth noting that 
although 45 patients with NVG were treated, 
only eyes with corneal edema developed CEDs 
regardless of the dose and volume of IVB, 
or intraocular pressure (IOP) level. After the 
development of CED, all cases were treated with 
occlusion (eye patching or therapeutic contact 
lenses) and topical antibiotics. The healing 
period ranged from 3 to 38 days (mean, 11 
days). The condition was further complicated 
in one eye by an infectious keratitis, 3 days 
after IVB, which was successfully treated with 
topical vancomycin.
Experimental Study
Figures  1  through  4  depict  a  delay  in 
wound healing in rabbit eyes treated with 
bevacizumab and corticosteroids (groups A and 
B, respectively) as compared to those treated 
with antibiotics alone (group C). Complete 
healing of the cornea was observed after 48 
Figure 2. Comparison of CED healing time among all 
treatment groups.
hours in group C (Figures 1 and 2). However, 
bevacizumab and corticosteroid-treated corneas 
healed after 72 hours. Twelve hours after PRK, 
a significant difference in healing was observed 
between groups A and B as compared to group 
C (both P values < 0.0001); groups A and B, 
however were comparable (P=0.65). Similar 
Figure 3. Comparison of CED healing time between the 
bevacizumab  and  antibiotics  groups  at  different  time 
points.Epithelial Defects after IVB; Colombres et al
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intergroup differences were observed at 24 
hours (groups A and C, P=0.02; groups B and 
C, P=0.02; groups A and B, P=0.85; Figures 3, 
4, and 5).
Corneas without PRK (the untreated fellow 
eyes) were not affected by any of the three 
treatment regimens.
DISCUSSION
Increased  vascular  permeability  and 
neovascularization are major causes of 
visual loss in exudative AMD and diabetic 
retinopathy. Although anti-VEFG therapy 
has yielded promising results for treatment 
Figure 5. Comparison of CED healing time between the 
bevacizumab and corticosteroid groups at different time 
points.
Figure 4. Comparison of CED healing time between the 
steroid and antibiotics groups at different time points.Epithelial Defects after IVB; Colombres et al
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of these diseases,12,21 complications have been 
reported.22 Wong et al22 reported three eyes 
with adverse corneal events after IVB. In one 
of these cases, corneal edema developed 30 
days after the injection.
In the current study seven eyes developed 
CEDs 24 hours after injection of different doses 
of IVB. All eyes demonstrated delayed healing 
even though intensive occlusive treatment 
was performed in all cases. A common factor 
in all patients was preexisting corneal edema. 
Although other risk factors for development of 
corneal ulceration (such as the use of antiseptic 
solutions or elevated IOP due to IVB injection) 
existed in this setting, it is worth noting 
that none of the eyes without corneal edema 
developed CEDs. Regarding IOP elevation, it is 
interesting that although 45 patients with NVG 
were treated, only eyes with corneal edema 
developed corneal ulceration. This occurred 
regardless of the dose and volume of IVB or 
IOP level.
Corneal stromal and epithelial edema, lead 
to attenuation or rupture in Bowman’s layer 
and the epithelial basement membrane.23,24 
This predisposes to poor epithelial adhesion 
and formation of subepithelial bullae which 
in turn cause persistent epithelial defects. A 
vicious cycle of epithelial breakdown and 
wound healing produces a state of chronic 
inflammation. Inhibition of VEGF may adversely 
affect corneal physiology and predispose to 
development of an inflammatory state and 
impaired wound healing.
There is a possibility of mild reflux of 
bevacizumab from the intraocular compartment 
onto the ocular surface after IVB is injected. 
This scenario is more likely to occur in eyes 
with high IOP, since intraocular pressure has 
been described, among several other factors, 
to influence the development of reflux.25 It 
is worth noting that 4 of the 7 patients who 
developed CED presented with NVG and high 
IOP levels.
We demonstrated experimentally that 
topical bevacizumab delayed wound healing 
in rabbit corneas in a PRK model, which was 
comparable to the effect of topical corticosteroids.
Following corneal injury, a combination 
of rapid signal transduction events and cell 
migration are essential for wound healing.26 
This involves epithelial proliferation, migration 
and stratification, and stromal wound healing.27 
Cytokines, growth factors, and several matrix 
degrading enzymes participate in tissue 
degradation, which is associated with corneal 
inflammation and wound healing.
VEGF and the vascular endothelial growth 
factor receptor 2 (VEGFR-2) are active in 
the epithelial wound healing phase, and are 
expressed in proliferating corneal epithelium, 
keratocytes, and endothelium.28 Gan et al28 
showed that expression of VEGF decreased and 
nearly disappeared in the corneal epithelium 
immediately peripheral to the leading edge, 
while at the wound edge epithelial cells 
strongly expressed this receptor. There is a 
possibility that topical bevacizumab applied 
on the wounded rabbit corneas inhibited the 
effect of VEGF on the proliferating epithelium, 
thus delaying healing. In clinical settings, the 
intravitreal injection of bevacizumab may 
have caused spillage over the ocular surface 
and created the same effect on the edematous 
corneas of our seven patients.
Another possible explanation for the 
delay in healing could be related to the effect 
of bevacizumab on corneal nerves during 
wounding. Corneal nerves are of great 
importance due to their role in protecting 
the cornea from irritants and because of their 
trophic properties, which are necessary to 
maintain a healthy ocular surface.29 Disruption 
of corneal nerves has been shown to impair 
corneal healing significantly.30 VEGF has 
also been demonstrated to be an important 
factor for nerve growth; in vitro experiments 
have shown that VEGF and its receptor are 
expressed by neurons, and that they stimulate 
neurogenic, neuroprotective, and neurotrophic 
activities.31 VEGF may also have an important 
role in corneal healing, possibly by promoting 
or guiding nerve growth. Inhibition of VEGF 
has previously been shown to reduce the 
serum dependent growth of cultured neurons 
by 17%. More importantly, by adding VEGF 
neutralizing antibodies to corneas undergoing 
sub-basal nerve plexus regeneration, neuronal Epithelial Defects after IVB; Colombres et al
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repair was inhibited by 23%.32
Corneal wound healing is associated with 
expression of adhesion molecules, such as 
integrins that mediate interactions between 
contiguous cells and/or the extracellular matrix 
(ECM) and thus, modify cellular properties such 
as proliferation, migration, differentiation and 
apoptosis.33 A recent report demonstrated that 
bevacizumab delayed corneal wound healing 
and inhibited the expression of integrin.34 
Integrin alpha 5 beta 1 is the classical receptor 
for fibronectin and under optimal conditions, 
mediates cellular attachment to the ECM.35 
VEGFR-1, a soluble tyrosine kinase receptor 
for VEGF, is present within the extracellular 
matrix and is able to interact with alpha 5 
beta 1 integrin. Moreover, alpha 5 integrin has 
been reported to enhance migration by binding 
directly to VEGFR-1.36 Inhibition of VEGF 
probably interferes with the normal function 
of fibronectin and disturbs cellular attachment 
of the corneal epithelium to Bowman layer and 
thus, delays corneal re-epithelialization.
To our knowledge, the current study is 
the first to report corneal edema as a risk 
factor for development of corneal epithelial 
defects after IVB injections. Delayed epithelial 
healing was probably related to bevacizumab 
as demonstrated experimentally in our rabbit 
model of PRK-induced CED. Although certain 
pathways involved in corneal epithelial healing, 
cell adhesion and neurotrophic mechanisms 
may play a role, the precise mechanisms of 
this inhibition are not yet well established. 
Physicians should bear in mind that this drug 
can delay wound healing and should therefore 
be cautious when applying bevacizumab to any 
compromised ocular surface.
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